Cognivia
Summary
Promising compounds fail trials not because the drug doesn't work, but because placebo responders and dropout noise drown out the efficacy signal — and most analytics platforms hand you a report after the damage is done. Cognivia exists to catch those behavioral risks before they invalidate your study.
Cognivia operates as two linked products: Signal, an early-warning dashboard that flags participants at high dropout risk and monitors placebo response drivers in real time, and Placebell, a covariate adjustment method that statistically accounts for behavioral and contextual factors inflating placebo variance. In a published Type 1 diabetes trial, Signal identified the majority of eventual dropouts as high-risk before they left — giving retention teams a window to act. Placebell's covariate approach delivered measurable precision gains in an osteoarthritis study, translating to fewer patients needed for equivalent statistical power. The platform is cloud-only, has no API, and is not self-hosted — meaning integration with your existing EDC or CTMS is a conversation with the Cognivia team, not a configuration file.
Bottom line: Cognivia fits a Phase II or Phase III sponsor who needs to defend efficacy signals against behavioral noise; it does not fit a team that needs to pipe trial data through their own infrastructure or run the platform inside a firewall.
Pricing Plans
Enterprise
Custom solutions for clinical trials including Signal and Placebell
- Real-time dashboards
- Covariate adjustment
- Behavioral risk monitoring
View full pricing on cognivia.com →
Pricing may have changed since last verified. Check the official site for current plans.
Community Performance Report Card
No community ratings yet. Be the first to rate this tool!
Pros
Sign in to edit- Early dropout risk scoring from behavioral data during an active trial, so retention teams have a specific list of at-risk participants to contact before they leave — rather than retrospective dropout analysis that cannot change outcomes.
- Placebell covariate adjustment reduces placebo-driven variance statistically, which means sponsors can demonstrate equivalent precision with fewer enrolled patients — directly cutting recruitment cost and timeline in indication areas with high placebo response rates.
- Machine learning models trained on behavioral and contextual variables, not just demographic splits, so the risk scores reflect how participants actually behave in-trial rather than baseline characteristics alone.
- Real-time dashboard monitoring of placebo response drivers throughout the study, which means clinical development teams can document behavioral trends for regulatory submissions rather than relying on post-hoc explanations of efficacy signal dilution.
Cons
Sign in to edit- No API and no self-hosted option means data must flow through Cognivia's cloud environment — teams operating under strict data residency mandates or needing automated integration with an existing EDC pipeline cannot deploy this without a custom vendor engagement, and some will not be able to deploy it at all.
- Both products are analytics and statistical methodology layers, not a full trial management system — a team expecting this to replace or natively connect to their CTMS, randomization platform, or ePRO tooling will need to build and maintain a separate data transfer process, adding operational overhead rather than removing it.
- The case study evidence base covers specific indication areas (Type 1 diabetes, osteoarthritis); sponsors running trials in indications where behavioral drivers of placebo response are less established have no published validation to present to a biostatistics or regulatory reviewer, which forces an internal validation study before Placebell outputs can anchor a primary analysis — at which point some teams switch to a traditional covariate adjustment approach their existing biostatistics team already controls.
About
- API Available
- No
- Self-Hosted
- No
- Last Updated
- 2026-08-16T16:11:20.123Z
Best For
Who it's for
- Clinical trial sponsors
- Pharma and biotech companies
- Clinical development teams
What it does well
- Monitoring behavioral risks in clinical trials
- Adjusting for placebo response variability
- Reducing participant dropout
- Improving statistical power and data interpretation
Add notes, reviews, and benchmarks so the next visitor gets a clearer picture.
Compare Cognivia
Spotted incorrect or missing data? Join our community of contributors.
Sign Up to ContributeFrequently Asked Questions
- Is Cognivia free?
- Cognivia is a paid tool. No permanent free tier is offered.
- Is Cognivia open source?
- No — Cognivia is a closed-source tool. Source code is not publicly available.
Curated lists that include this category
Placebo noise and late dropouts drown trial signals
Promising compounds fail trials not because the drug doesn’t work, but because placebo responders and dropout noise drown out the efficacy signal — and most analytics platforms hand you a report after the damage is done. Cognivia exists to catch those behavioral risks before they invalidate your study.
Two linked products
Cognivia operates as two linked products: Signal, an early-warning dashboard that flags participants at high dropout risk and monitors placebo response drivers in real time, and Placebell, a covariate adjustment method that statistically accounts for behavioral and contextual factors inflating placebo variance. In a published Type 1 diabetes trial, Signal identified the majority of eventual dropouts as high-risk before they left — giving retention teams a window to act. Placebell’s covariate approach delivered measurable precision gains in an osteoarthritis study, translating to fewer patients needed.
Use cases and trade-offs
Key uses include monitoring behavioral risks in clinical trials, adjusting for placebo response variability, reducing participant dropout, and improving statistical power and data interpretation. Early dropout risk scoring from behavioral data during an active trial gives retention teams a specific list of at-risk participants to contact before they leave. Placebell reduces placebo-driven variance statistically so sponsors can reach equivalent precision with fewer enrolled patients. Machine learning models focus on behavioral and contextual variables, not just demographics. Limits include no API and no self-hosted option, so data must flow through Cognivia’s cloud; teams with strict data residency rules or existing EDC pipelines face extra custom work or cannot deploy at all. The tools are analytics layers only, not a full trial management system, so users must maintain separate data transfers to CTMS or ePRO platforms.
Who it is for / who should skip it
Best for clinical trial sponsors, pharma and biotech companies, and clinical development teams. Skip it if you require an API, self-hosted deployment, or native replacement for a full trial management system.